Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

• Register: ClinicalTrials.gov
• Last refreshed on: 11 October 2021
• Main ID: NCT02833766
• Date of registration: 12/07/2016
• Prospective Registration: Yes
• Primary sponsor: Swiss Group for Clinical Cancer Research
• Public title: Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
• Scientific title: Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial
• Date of first enrolment: October 28, 2016
• Target sample size: 48
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT02833766
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Switzerland

Contacts

• Name: Ralph Winterhalder, MD
• Affiliation: Luzerner Kantonsspital

Key inclusion & exclusion criteria

Inclusion Criteria:

- Written informed consent according to ICH/GCP regulations before prescreening and
registration and prior to any trial specific procedures, including participation in
mandatory translational research

- Histologically proven diagnosis of TNBC in metastatic or locally advanced non operable
stage

- EGFR expression in primary tumor or metastases of at least (1+) in
immunohistochemistry, assessed by central pathologist

- Measurable or evaluable disease according to RECIST 1.1

- No prior systemic treatment for metastatic or inoperable disease

- Adequate bone marrow function: neutrophils = 1.5 x 109/L, platelets = 100 x 109/L

- Adequate hepatic function: total bilirubin = 1.5 x ULN; AST, ALT and AP = 2.5 x ULN
(AST, ALT and AP = 5 x ULN if hepatic metastases are the only reason for enzyme
elevation)

- Adequate renal function: serum creatinine = 1.5 x ULN and calculated creatinine
clearance > 30 mL/min, according to the formula of Cockcroft-Gault.

- Adequate cardiac function: Left Ventricular Ejection Fraction (LVEF) = 40% as
determined by either echocardiography (ECHO) or radionuclide angiocardiography (MUGA)

Exclusion Criteria:

- Evidence of CNS or leptomeningeal metastases (even if previously treated); CNS imaging
not required in asymptomatic patients

- History of hematologic or primary solid tumor malignancy, unless in remission for at
least 5 years from registration. Inclusion of adequately treated cervical carcinoma in
situ or localized non-melanoma skin cancer is permitted independent of time since
diagnosis

- Previous therapy with more than 240 mg/m2 of doxorubicin or more than 450 mg/m2 of
epirubicin

- Previous radiotherapy for the metastatic disease (palliative radiotherapy of only
non-target lesions is allowed)

- Adjuvant treatment must have been stopped at least 6 months before registration

- Any serious underlying medical condition (at the judgement of the investigator) which
could impair the ability of the patient to participate in the trial (e.g. active
autoimmune disease, uncontrolled diabetes, etc.)

- Breastfeeding

- Participation in any investigational drug trial within 4 weeks preceding treatment
start

- Any concomitant drugs contraindicated when administering Erbitux™ or Caelyx™ according
to the Swissmedic-approved product information

- Known hypersensitivity to trial drug(s) or to any component of the trial drug(s)

- Any other serious underlying medical, psychiatric, psychological, familial or
geographical condition, which in the judgment of the investigator may interfere with
the planned staging, treatment and follow-up, affect patient compliance or place the
patient at high risk from treatment-related complications.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Breast Cancer

Intervention(s)

Drug: anti-EGFR-IL-dox

Primary Outcome(s)

Progression-free survival (PFS) [Time Frame: at 12 months after registration]

Secondary Outcome(s)

Objective response rate (ORR) [Time Frame: at 12 months after registration]

Duration of response (DOR) [Time Frame: at 12 months after registration]

Adverse events (AEs) [Time Frame: at 12 months after registration]

Overall survival (OS) [Time Frame: at 12 months after registration]

PFS [Time Frame: at 12 months after registration]

Time to Progression (TTP) [Time Frame: at 12 months after registration]

Secondary ID(s)

SAKK 24/14

Source(s) of Monetary Support

Please refer to primary and secondary sponsors